Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients.

@article{Arida2011AntiTNFAF,
  title={Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients.},
  author={Aikaterini Arida and Kalliopi Fragiadaki and Eirini Giavri and Petros P. Sfikakis},
  journal={Seminars in arthritis and rheumatism},
  year={2011},
  volume={41 1},
  pages={61-70}
}
OBJECTIVE Off-label use of anti-tumor necrosis factor (TNF) agents for Behçet's disease (BD) is increasing. We evaluated published data on their efficacy and safety for patients with unmet medical needs due to severe disease manifestations, including ocular, gastrointestinal, and central nervous system involvement. METHODS Peer-reviewed articles on anti-TNF agents for BD appearing in Medline/PubMed through March 2010 were identified using the appropriate indexing terms. RESULTS We found 88… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Combination of infliximab with azathioprine and/or cyclosporine - A appeared superior to monotherapy for sustained ocular remission .
Combination of infliximab with azathioprine and/or cyclosporine - A appeared superior to monotherapy for sustained ocular remission .
Combination of infliximab with azathioprine and/or cyclosporine - A appeared superior to monotherapy for sustained ocular remission .
Combination of infliximab with azathioprine and/or cyclosporine - A appeared superior to monotherapy for sustained ocular remission .
Combination of infliximab with azathioprine and/or cyclosporine - A appeared superior to monotherapy for sustained ocular remission .
Combination of infliximab with azathioprine and/or cyclosporine - A appeared superior to monotherapy for sustained ocular remission .
Combination of infliximab with azathioprine and/or cyclosporine - A appeared superior to monotherapy for sustained ocular remission .
Combination of infliximab with azathioprine and/or cyclosporine - A appeared superior to monotherapy for sustained ocular remission .
Combination of infliximab with azathioprine and/or cyclosporine - A appeared superior to monotherapy for sustained ocular remission .
Combination of infliximab with azathioprine and/or cyclosporine - A appeared superior to monotherapy for sustained ocular remission .
We found 88 , 12 , and 13 primary articles from 20 countries on infliximab , etanercept , and adalimumab , reporting on 325 , 37 , and 28 patients , respectively .
We found 88 , 12 , and 13 primary articles from 20 countries on infliximab , etanercept , and adalimumab , reporting on 325 , 37 , and 28 patients , respectively .
We found 88 , 12 , and 13 primary articles from 20 countries on infliximab , etanercept , and adalimumab , reporting on 325 , 37 , and 28 patients , respectively .
We found 88 , 12 , and 13 primary articles from 20 countries on infliximab , etanercept , and adalimumab , reporting on 325 , 37 , and 28 patients , respectively .
We found 88 , 12 , and 13 primary articles from 20 countries on infliximab , etanercept , and adalimumab , reporting on 325 , 37 , and 28 patients , respectively .
We found 88 , 12 , and 13 primary articles from 20 countries on infliximab , etanercept , and adalimumab , reporting on 325 , 37 , and 28 patients , respectively .
All Topics